Manager TitleAgeSince
Chief Executive Officer - -
Corporate Secretary - -
Corporate Officer/Principal - 2020-11-16
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
20-11-16Tender

Director

93,908 0.1762%
20-11-16Tender

President and CEO; Director

1,835,985 3.4441%
20-11-16Tender

General Counsel

105,000 0.1970%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%+0.16% - - 11.99B
-0.61%-2.06%+65.94%+120.29% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.78%+14.77%+37.54%-1.86% 17.32B
+0.22%+3.14%+29.85%-32.64% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+4.21%+11.01%+33.13% - 12.43B
Average +1.13%+4.78%+43.90%+130.48% 25.14B
Weighted average by Cap. +0.78%+5.13%+49.82%+121.99%
Logo MyoKardia, Inc.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYOK Stock